Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-25-109222
Filing Date
2025-11-12
Accepted
2025-11-12 16:17:17
Documents
16
Effectiveness Date
2025-11-12

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0265149-s8_nektar.htm S-8 51656
2 NEKTAR THERAPEUTICS 2025 INDUCEMENT PLAN AND FORMS OF STOCK OPTION AGREEMENT AND ea026514901ex4-8_nektar.htm EX-4.8 171561
3 OPINION OF GOODWIN PROCTER LLP WITH RESPECT TO THE VALIDITY OF THE SECURITIES ea026514901ex5-1_nektar.htm EX-5.1 6650
4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea026514901ex23-1_nektar.htm EX-23.1 1978
5 FILING FEE TABLE ea026514901ex-fee_nektar.htm   iXBRL EX-FILING FEES 12924
6 GRAPHIC ex5-1_001.jpg GRAPHIC 13199
  Complete submission text file 0001213900-25-109222.txt   383809

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT ea026514901ex-fee_nektar_htm.xml XML 4864
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-291471 | Film No.: 251473010
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)